Articles by William Looney - Pharmaceutical Executive

ADVERTISEMENT

Articles by William Looney

Three Ways to the Future

Oct 1, 2012

Developing a drug is still very much a game of chance: a round puzzle of soft edges, with pieces that rarely fit the hard rectangles of time and money. Solving the puzzle correctly—with a new product as the sum of its parts—depends on making that lengthy progression from basic science to registration as linear as possible.

The Margin Call

Sep 1, 2012

Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.

The Phrase that Plays

Aug 1, 2012

This month's feature by Ben Comer highlights what's behind the new Corporate Integrity Agreement (CIA) imposed on GSK by theHHS Office of Inspector-General to compensate for a long list of marketing and pricing malfeasances

Emerging Pharma Leaders: David Ford

Jul 30, 2012

Are there parallels between milk and medicine? To David Ford, a native New Zealander who now runs Sanofi's North America human resources operations, the answer is a qualified yes.

Less, But Better

Jul 1, 2012

Pharm Exec's 2012 roster of Emerging Leaders—our sixth to date—is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace.

Today's Mission Critical: Making Sense of Spending on Clinical Trials

Jul 1, 2012

Mastery of the clinical trial process has become essential to positioning new therapies for leadership in an increasingly crowded—and lengthy—race to registration.

The Learning Curve

Jul 1, 2012

In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises—change for pharma is here and its good.

2012 Dealmakers Outlook

Jun 1, 2012

Pharm Exec convened a panel of heavy hitters in business development to crack the bat on best practices in licensing and M&A for the year ahead.

From the Editor:The Connections Game

Jun 1, 2012

As the old Broadway song goes, June is busting out all over—and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous.

ADVERTISEMENT

Click here